Publications
NK Cells
G-Rex®24 Well Plate
Publication Date: November 1, 2022
Adaptive NKG2C+ NK cells carrying a single self-KIR, expanded from selected CMV-seropositive superdonors, killed HLA-C/KIR-mismatched leukemia cells efficiently and controlled acute myeloid leukemia in mice. Using CD3/CD19-depleted cryopreserved donor cells and irradiated K562 feeders expressing HLA-E, a GMP-compliant 11-day protocol produced a median 470-fold expansion, with some donors exceeding 1000-fold. On day 11, a median 91% of NK cells were NKG2C+ and 81% expressed a single self-KIR, while fewer than 20% expressed NKG2A. The cells largely kept their adaptive transcriptional signature without signs of exhaustion. In NSG mice bearing HL-60 leukemia, a single dose of 5 × 10^6 mismatc…
Publications
CAR T Cells
G-Rex®100M-CS
Publication Date: October 19, 2022
Repeated intraventricular infusions of autologous B7-H3 CAR T cells were feasible and well tolerated in the first children and young adults with diffuse intrinsic pontine glioma treated on the phase I BrainChild-03 trial (arm C). Products were manufactured for all five enrolled patients, with 7.84 × 10^8 to 4.54 × 10^9 CAR T cells after 10 to 13 days in culture, using methotrexate selection. Three evaluable patients received 40 infusions at 1 × 10^7 cells with no dose-limiting toxicity; headache, nausea/vomiting and fever were the most common related events. CAR T cells were detected in the cerebrospinal fluid of two of three patients, CSF cytokines such as CCL2 and CXCL10 rose, and one p…
Publications
CAR T Cells
G-Rex®6M Well Plate
Publication Date: October 18, 2022
A fully murine CAR against CD105 (endoglin) was built to study CAR-T biology in immunocompetent mice, using the B16 melanoma model. The T cells were expanded from C57BL/6J donors and activated specifically by CD105, killing CD105-positive but not CD105-negative targets in vitro. After cyclophosphamide conditioning, 3 million CAR-T cells caused rapid weight loss and a cytokine storm, whereas 500,000 cells were tolerated and engrafted at about 16-20% of circulating CD45+ cells. At this dose they slowed B16 growth and doubled survival. Tumor-infiltrating CAR-T cells showed high inhibitory receptor levels, impaired glucose uptake, lost mitochondrial mass and reduced surface CAR. A human CD105…
Publications
CAR T Cells
G-Rex®100
Publication Date: October 6, 2022
Cryopreservation of starting material or of CAR T cells during manufacturing did not appear to compromise production or clinical outcome for CD19 CAR T therapy. In 118 completed productions at one center, ten used thawed PBMCs and gave day-10 fold expansion and transduction comparable to fresh PBMCs, with objective responses in 80% versus 72%. Seven products frozen on day 6 to 8 resumed expansion after thaw, reached the target dose, and four patients achieved complete remission. Fresh infusion products showed higher in vitro reactivity in some assays, but thawed products still secreted far above 200 pg/ml IFNg, and cell recovery did not differ between responders and non-responders.
Publications
CAR T Cells, γδ T
Publication Date: September 26, 2022
Retrovirally transduced CD123-directed CAR Delta One T (DOT) cells eliminated CD123+ acute myeloid leukemia blasts far more potently than mock-transduced DOT cells, both in vitro and in patient-derived xenografts. Vδ1-enriched γδ T cells were generated from αβ-depleted healthy-donor mononuclear cells cultured 16-20 days in 96-well plates or the G-Rex® platform and transduced at day 7, keeping ~97% γδ TCR+ and ~70% Vδ1+ purity. Against the MOLM13 and THP-1 lines, CAR-DOTs achieved 20-60% more lysis than mock-DOTs even at 1:16 to 1:4 effector:target ratios, and released more TNF-α, IFN-γ and IL-13. In NSG mice carrying 2.5x10^5 AML-PDX cells, three weekly infusions of 10x10^6 CAR-DOTs contr…
Publications
NK Cells
G-Rex®6 Well Plate
Publication Date: September 26, 2022
A tri-specific killer engager targeting TEM8, named cam1615TEM8, directs natural killer cells against TEM8-expressing tumor and tumor stromal cells and outperforms IL-15 alone in preclinical models. The molecule combines an anti-CD16 camelid nanobody, an IL-15 moiety and an anti-TEM8 scFv. It triggered NK degranulation and IFNγ production against A549 and DU145 tumor lines, endothelial cells and fibroblasts, but not TEM8-negative HT-29 or Raji, and activity vanished when TEM8 was knocked out in A549. It induced similar NK cell proliferation to IL-15 but far less T cell proliferation. In NSG mice with A549 xenografts, NK cells plus cam1615TEM8 gave smaller tumors, longer survival, more cir…
Publications
CAR T Cells
Publication Date: September 9, 2022
Supplementing cultures with the kinase inhibitors ibrutinib (200 nM) and dasatinib (200 nM) prevented fratricide of CD7 CAR T cells made from unedited peripheral blood T cells, so that CD7 gene knockout was unnecessary. Treated cells kept high CAR expression, remained viable and expanded normally, and regained cytotoxicity against Jurkat and CCRF-CEM T-ALL lines once the inhibitors were withdrawn. In NSG mice engrafted with either leukemia, these cells persisted long term, controlled disease and prolonged survival, outgrowing as a CD7-negative population transcriptionally very similar to CD7-edited CAR T cells. Three autologous products manufactured under cGMP from patients with T-ALL exp…
Publications
CAR T Cells
Publication Date: August 29, 2022
Humanized CD19-directed CAR-T cells induced complete remission in children with relapsed/refractory acute lymphoblastic leukemia and central nervous system leukemia (CNSL) or neurological comorbidities, when tumor burden and neurological status were controlled before infusion. Among 12 prospectively treated patients (4 with CNSL, 3 with marrow relapse and comorbidity, 5 with marrow relapse alone), all 11 evaluable patients achieved complete remission on day 28 after one infusion of 1 × 10^6 CAR-T cells/kg. CAR-T cells were found in every cerebrospinal fluid sample on day 14, peaking at 39.5% of lymphocytes versus 16.2% in blood, and persisted there a median 5.5 months in CNSL versus 3 mon…
Publications
B Cells, CAR T Cells, CD34 Cells, NK Cells, T-Cells, Treg Cells, γδ T
G-Rex®100M
Publication Date: August 25, 2022
Hybrid repair templates that combine a long single-stranded DNA body with short double-stranded Cas9 target sites raised knock-in efficiency and live knock-in cell yield in primary human cells, generating up to sevenfold more knock-in cells than fully double-stranded templates at optimal concentrations. In T cells these templates reached 78.5% knock-in for a roughly 1.5 kb tNGFR construct and 39% for a roughly 2.9 kb BCMA-CAR construct at the TRAC locus. Across 44 constructs targeting 22 loci, adding the M3814, trichostatin A and XL413 cocktail raised knock-in efficiency by roughly 2.5-fold on average. A GMP-compatible run electroporated 100 × 10^6 T cells on day 2 and expanded them in G-…
Publications
TIL Cells
G-Rex®100
Publication Date: August 24, 2022
Deleting the intracellular checkpoint CISH with CRISPR/Cas9 makes human tumor-infiltrating lymphocytes more responsive to tumor neoantigens and to PD1 blockade. In single-cell data from seven melanoma TIL samples, high CISH expression went with lower activation markers. A GMP-compatible editing process gave over 95% CISH knockout in TIL with no off-target editing detected. In TIL from three gastrointestinal cancer patients, knockout raised cytokine production against mutant neoantigens, with IFN-γ and TNF-α double-positive cells rising from 17% to 51% in one patient, and restored a lost reactivity in another. Knockout also increased expansion without changing T cell maturation. In mice, C…
Publications
TIL Cells
G-Rex®6 Well Plate
Publication Date: July 12, 2022
An oncolytic adenovirus carrying human interleukin 7, Ad5/3-E2F-d24-hIL7, reduced tumor growth and increased T cell infiltration and activation in animal models and patient tumor cultures. Injected intratumorally into Syrian hamsters with pancreatic tumors, it produced smaller tumors than mock (p < .0001) and unarmed virus (p = .0463). In ovarian patient-derived xenografts in NOG mice, six treatment rounds gave smaller tumors than mock (p < .0001) and unarmed virus (p = .0001), and more tumor-infiltrating CD4+ and CD8+ cells than mock. In ex vivo patient ovarian cultures, the IL7 virus raised IFNg and chemokines, increased CD4+, CD8+ and NK cell migration, and raised granzyme B-posi…
Publications
TCR T Cells, TIL Cells
G-Rex®10
Publication Date: July 7, 2022
CD8 T cells with a tissue-resident memory program were the early responders to neoadjuvant checkpoint blockade in oral cavity cancer. In a phase 2 trial of anti-PD-1 alone or with anti-CTLA-4, single-cell RNA and TCR sequencing of 74,557 tumor immune cells showed that clones expanding during therapy concentrated in ITGAE-positive and cycling CD8 clusters, with a mean of 59.1% pre-existing and 40.9% emergent clonotypes. Expanded TCRs recognized self-antigens, including a MAGEA1 epitope presented by HLA-C*07:02. Combination therapy raised emergent blood clonotypes more than monotherapy. Pretreatment frequency of activated CD38+ HLA-DR+ blood CD8 T cells, and of PD-1-positive KLRG1-negative…
No manuscripts match your filters.